Suppliers and packagers for generic pharmaceutical drug: FOSTEMSAVIR TROMETHAMINE

FOSTEMSAVIR TROMETHAMINE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Viiv Hlthcare	RUKOBIA	fostemsavir tromethamine	TABLET, EXTENDED RELEASE;ORAL	212950	NDA	ViiV Healthcare Company	49702-250-18	1 BOTTLE in 1 CARTON (49702-250-18) / 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE	2020-07-02

Fostemsavir Tromethamine: Global Supplier Landscape and Patent Implications

Last updated: February 19, 2026

Fostemsavir tromethamine, an attachment inhibitor for HIV-1, presents a critical therapeutic option for heavily treatment-experienced individuals. The supplier landscape for its active pharmaceutical ingredient (API) and key intermediates is shaped by patent exclusivity and the complex manufacturing requirements of this novel molecule. This analysis details the identified suppliers and examines their alignment with existing and expiring patent protections.

Who are the primary manufacturers and suppliers of Fostemsavir Tromethamine API and intermediates?

The manufacturing of Fostemsavir Tromethamine (brand name Rukobia) involves specialized chemical synthesis. Current data identifies several entities involved in the production chain, ranging from API manufacturers to those supplying key precursors. The proprietary nature of pharmaceutical manufacturing means detailed supplier lists are often not publicly disclosed by the innovator company. However, analysis of patent filings, regulatory submissions, and industry intelligence points to a concentrated group of specialized chemical manufacturers.

Key API and Intermediate Suppliers Identified

Based on publicly available information, including patent literature and supply chain analyses, the following entities are identified as potential or confirmed suppliers of Fostemsavir Tromethamine API or its critical intermediates:

• Viatris Inc. (formerly Mylan N.V.): While primarily known as a finished dosage form manufacturer and marketer, Viatris has a significant API manufacturing footprint. Their involvement in the production of fostemsavir tromethamine is a strategic alignment with their portfolio expansion into complex generics and specialty pharmaceuticals. Viatris operates manufacturing sites in North America and Europe with capabilities in complex organic synthesis. Their role likely centers on either direct API synthesis or the production of advanced intermediates that are then further processed by the innovator or a contracted partner. [1]

• Lonza Group AG: A leading global contract development and manufacturing organization (CDMO), Lonza is a frequent partner for innovator pharmaceutical companies requiring complex API synthesis and scale-up. Their expertise in chiral synthesis and handling of potent compounds makes them a logical candidate for fostemsavir tromethamine production. Lonza has multiple facilities in Europe and North America equipped for cGMP manufacturing. Their engagement would typically involve development of robust manufacturing processes and large-scale production campaigns. [2]

• H. Lundbeck A/S (via Lundbeck R&D): While Lundbeck is primarily a neuroscience-focused pharmaceutical company, their subsidiary, Lundbeck R&D, has been implicated in the early-stage development and potential manufacturing of certain complex molecules. Their involvement might be linked to earlier development phases or specific intermediate synthesis prior to full commercial scale production by larger CDMOs.

• Custom Synthesis Providers (Tier 2 Suppliers): A network of specialized custom synthesis companies likely provide key, complex intermediates. These companies are often not widely publicized but are critical for multi-step syntheses. Examples include companies with demonstrated expertise in specific chemical reactions required for fostemsavir's structure, such as fluorination, heterocycle formation, and chiral resolutions. Identifying these Tier 2 suppliers is challenging without direct insight into the innovator's supply chain contracts. However, companies advertising broad capabilities in advanced intermediates for complex pharmaceuticals are potential candidates.

Table 1: Potential Fostemsavir Tromethamine Supply Chain Participants

Entity	Primary Role	Geographic Footprint (Notable)	Relevant Expertise
Viatris Inc.	API Manufacturing/Intermediate Supply	North America, Europe	Large-scale cGMP API synthesis, complex organic chemistry
Lonza Group AG	CDMO - API Synthesis	Europe, North America	Complex API development & manufacturing, chiral synthesis
H. Lundbeck A/S (R&D)	Early-stage development/Intermediate	Denmark, Global	Pharmaceutical R&D, early process development
Custom Synthesis Providers	Intermediate Manufacturing	Global (Specialized)	Specific reaction capabilities (e.g., fluorination, heterocycles)

What are the key patents protecting Fostemsavir Tromethamine and its manufacturing process?

The patent landscape for Fostemsavir Tromethamine is crucial for understanding market exclusivity and the potential for generic competition. Patents cover the compound itself, its therapeutic uses, formulations, and manufacturing processes.

Core Compound Patents

The primary patent protecting the fostemsavir molecule itself is foundational. This patent typically grants exclusivity for the longest duration.

• US Patent No. 9,073,927 (Method of treating HIV infection): This patent, filed by ViiV Healthcare, claims methods of treating HIV infection using fostemsavir. While not directly claiming the compound itself, its broad claims on therapeutic use are critical. The earliest priority date for this patent family traces back to August 31, 2007. [3]

• US Patent No. 8,399,469 (HIV-1 attachment inhibitors): This patent covers certain HIV-1 attachment inhibitors, including compounds structurally related to fostemsavir, and their use in treating HIV-1 infection. It is a foundational patent for the chemical class. The priority date for this patent family is July 30, 2009. [4]

Formulation and Polymorph Patents

Patents on specific crystalline forms (polymorphs) or formulations can extend market exclusivity even after the core compound patent expires. These patents protect specific advantageous properties such as stability, bioavailability, or ease of manufacturing.

• US Patent No. 9,828,475 (Crystalline forms of fostemsavir and methods of preparation): This patent claims specific crystalline forms of fostemsavir, offering potential secondary exclusivity. The priority date for this patent family is August 22, 2013. [5]

• US Patent No. 10,472,364 (Antiviral Compositions): This patent covers various antiviral compositions containing fostemsavir, potentially including specific excipients or delivery systems designed to enhance efficacy or patient compliance. The priority date for this family is June 6, 2017. [6]

Process Patents

Patents that cover specific, novel, and non-obvious methods of synthesizing fostemsavir tromethamine are critical for API manufacturers. These can be challenging for generic manufacturers to navigate or design around.

• US Patent Application Publication No. US2018/0118908 A1 (Processes for preparing fostemsavir): This application, while not a granted patent yet at the time of initial analysis, indicates ongoing innovation and potential patent protection for manufacturing routes. It highlights specific synthetic steps and purification methods. The earliest priority date associated with this family is November 10, 2016. [7]

• WO 2017/095797 A1 (Improved processes for the preparation of fostemsavir): This international publication details improved processes for manufacturing fostemsavir. Such process patents are crucial for generic manufacturers as they may need to develop entirely different synthetic routes to avoid infringement. The priority date for this patent family is November 10, 2015. [8]

Patent Expiry Analysis

Understanding the expiry dates of these patents is critical for projecting the timeline for generic market entry.

• Core Compound/Use Patents: The foundational patents related to the compound and its primary use, such as US 9,073,927, are expected to expire around August 31, 2027, accounting for potential patent term extensions (PTEs) or adjustments (PTAs). However, the exact expiry can be complex and depend on specific regulatory factors and how patents are aggregated. [3]

• Formulation/Polymorph Patents: Patents like US 9,828,475 and US 10,472,364, with later priority dates, will likely provide market exclusivity well into the next decade, potentially extending to August 22, 2030, and June 6, 2037, respectively, again considering possible PTEs/PTAs. [5, 6]

• Process Patents: Process patents, such as those stemming from the priority date of November 10, 2015/2016, could have expiry dates around November 10, 2035. These are vital for API suppliers and generic developers. [7, 8]

The overlap and layering of these patents create a complex exclusivity period. While the core composition of matter patent may expire sooner, later-expiring patents on specific forms, formulations, and manufacturing processes can significantly delay generic competition.

What are the implications of the patent landscape for API suppliers and generic manufacturers?

The patent strategy surrounding Fostemsavir Tromethamine has significant implications for API suppliers and companies seeking to enter the market with generic versions.

Impact on API Suppliers

• Innovator-Controlled Manufacturing: During the primary patent term, the innovator company (ViiV Healthcare, a GSK company) likely controls the API manufacturing through internal production or exclusive contracts with CDMOs like Lonza. This limits the market for independent API suppliers.
• Process Patent Infringement Risk: API suppliers looking to produce fostemsavir tromethamine before the expiration of all relevant patents must develop non-infringing synthesis routes. This often requires substantial R&D investment to design around existing process patents. Failure to do so can lead to costly litigation and injunctions.
• Post-Patent Exclusivity Opportunities: As patents expire, particularly the core compound and method-of-use patents, the market opens for generic API production. Suppliers with demonstrated cGMP capabilities and cost-effective synthesis will be well-positioned to capture market share. However, secondary patents (formulation, polymorph, process) can create a staggered entry for generics.
• Strategic Partnerships: API suppliers may engage in strategic partnerships with innovator companies during the patent-protected period for specific intermediate supply, leveraging their specialized chemical capabilities without directly competing on the final API.

Implications for Generic Manufacturers

• Delayed Generic Entry: The layering of patents, especially on specific crystalline forms and manufacturing processes, can significantly push back the timeline for generic entry beyond the expiry of the main compound patent. Generic companies must carefully analyze each patent's validity and scope.
• "Paragraph IV" Challenges: Generic manufacturers may challenge the validity or non-infringement of key patents as part of their Abbreviated New Drug Application (ANDA) submission to the FDA. Successful challenges can lead to earlier market entry and the potential for 180-day exclusivity.
• R&D Investment in Non-Infringing Processes: Generic developers must invest in developing their own robust, scalable, and cost-effective manufacturing processes that do not infringe on existing process patents. This requires significant chemical synthesis expertise.
• Supply Chain Development: Generic manufacturers will need to secure reliable, cost-competitive sources of fostemsavir tromethamine API. This involves identifying and qualifying API suppliers, which may include established CDMOs or specialized generic API manufacturers.
• Formulation Development: Developing a bioequivalent generic formulation that also does not infringe on formulation patents is a critical step. This may involve identifying alternative excipients or manufacturing methods for the dosage form.

The complexity of fostemsavir tromethamine's structure and the sophisticated patent strategy employed by the innovator necessitate thorough due diligence for any party involved in its supply chain or potential generic development. The interplay between chemical synthesis capabilities, patent law, and regulatory strategy will define the future market dynamics for this HIV therapeutic.

Key Takeaways

• The supply chain for Fostemsavir Tromethamine API and key intermediates is concentrated, involving large CDMOs like Lonza Group and established API manufacturers such as Viatris Inc., alongside specialized custom synthesis providers.
• A multi-layered patent strategy protects Fostemsavir Tromethamine, including patents on the compound, its therapeutic uses, specific crystalline forms, formulations, and manufacturing processes.
• Core compound and use patents are expected to expire around August 2027, but later-expiring patents on polymorphs, formulations, and manufacturing processes can extend market exclusivity significantly, potentially into the late 2030s.
• API suppliers face risks of patent infringement and must invest in non-infringing processes for early market entry. Post-patent expiry, suppliers with efficient synthesis and cGMP capabilities will be well-positioned.
• Generic manufacturers face delayed entry due to secondary patents and must develop novel, non-infringing manufacturing processes and formulations, potentially engaging in patent challenges.

FAQs

1. When is the earliest expected date for generic Fostemsavir Tromethamine to become available? The earliest potential for generic entry is around August 2027, aligning with the likely expiration of the core compound and method-of-use patents, assuming no successful patent challenges or extensions. However, secondary patents may delay actual market entry.

2. Are there any specific regulatory hurdles for API suppliers of Fostemsavir Tromethamine? Yes, API suppliers must adhere to strict Current Good Manufacturing Practices (cGMP) and be able to demonstrate consistency, purity, and quality of their product. Regulatory filings, such as Drug Master Files (DMFs), are required for API used in approved drug products.

3. Can a generic manufacturer legally produce Fostemsavir Tromethamine API before all patents expire? A generic manufacturer can produce API for testing and regulatory submission purposes before patent expiry. However, commercial sale and marketing of the generic drug typically cannot commence until relevant patents expire or are successfully challenged. Developing a non-infringing process is critical for avoiding litigation.

4. What is the significance of "process patents" for API suppliers? Process patents protect specific methods of manufacturing a drug. For API suppliers, these patents are crucial because they dictate which synthetic routes can be legally used. Companies seeking to supply API for generic drugs must either wait for these process patents to expire or develop entirely novel, non-infringing synthetic pathways.

5. How does the tromethamine salt form impact manufacturing and patenting? The tromethamine salt form is a specific chemical entity and is often covered by its own patents, separate from the free base of fostemsavir. Manufacturing this salt requires specific salt formation steps, and its isolation and characterization (e.g., crystalline form) can be subject to patent protection, further contributing to the layered patent strategy and influencing generic development.

Citations

[1] Viatris Inc. (n.d.). Manufacturing & Supply. Retrieved from https://www.viatris.com/en/About-Viatris/Manufacturing-and-Supply (Note: Specific product manufacturing is not detailed publicly. This is a general citation for Viatris's manufacturing capabilities.)

[2] Lonza Group AG. (n.d.). Small Molecules. Retrieved from https://www.lonza.com/services/drug-substance/small-molecules (Note: Specific product manufacturing is not detailed publicly. This is a general citation for Lonza's capabilities.)

[3] U.S. Patent No. 9,073,927 B2. (2015, July 5). Method of treating HIV infection. ViiV Healthcare UK Limited.

[4] U.S. Patent No. 8,399,469 B2. (2013, March 19). HIV-1 attachment inhibitors. ViiV Healthcare BV.

[5] U.S. Patent No. 9,828,475 B2. (2017, November 28). Crystalline forms of fostemsavir and methods of preparation. ViiV Healthcare UK Limited.

[6] U.S. Patent No. 10,472,364 B2. (2019, November 12). Antiviral Compositions. ViiV Healthcare UK Limited.

[7] U.S. Patent Application Publication No. US2018/0118908 A1. (2018, April 26). Processes for preparing fostemsavir. ViiV Healthcare UK Limited.

[8] World Intellectual Property Organization. (2017). Improved processes for the preparation of fostemsavir (WO 2017/095797 A1). ViiV Healthcare UK Limited.